Phenomenal news. Not just the news itself, but this news also provides evidence that operations are still running and growth is still a focus now and not just later. That’s not to say COVID-19 won’t have an impact, but I’m glad to see it hasn’t halted all progress for MediPharm.
The anticipation for the earnings call on Monday is growing. I think if we can get solid Q4 results and at least some mild optimism about 2020 that would be huge right now for the price action. If not, this could take longer to rebound, but I will be here either way most likely.